Tempest Therapeutics (TPST) Stock Price, News & Analysis

Company Overview

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.

Key Stats

• Today's Range: $0.87 to $0.89
• 50-Day Range: $0.85 to $1.51
• 52-Week Range: $0.80 to $6.00
• Volume: 137,454 shs
• Average Volume: 2.10 million shs
• Market Capitalization: $22.43 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $20.00
• Consensus Rating: Buy

Tempest Therapeutics Stock Analysis - MarketRank™

Tempest Therapeutics scored higher than 45% of companies evaluated by MarketBeat, and ranked 562nd out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Tempest Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Tempest Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Tempest Therapeutics are expected to grow in the coming year, from ($1.38) to ($1.00) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Tempest Therapeutics is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Tempest Therapeutics is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Tempest Therapeutics has a P/B Ratio of 2.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

11.82% of the float of Tempest Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Tempest Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Tempest Therapeutics has recently decreased by 29.03%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tempest Therapeutics does not currently pay a dividend.

Dividend Growth

Tempest Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

11.82% of the float of Tempest Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Tempest Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Tempest Therapeutics has recently decreased by 29.03%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: -0.17

News Sentiment

Tempest Therapeutics has a news sentiment score of -0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for Tempest Therapeutics this week, compared to 1 article on an average week.

Search Interest

Only 15 people have searched for TPST on MarketBeat in the last 30 days. This is a decrease of -46% compared to the previous 30 days.

MarketBeat Follows

19 people have added Tempest Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 171% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Tempest Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.70% of the stock of Tempest Therapeutics is held by insiders.

Percentage Held by Institutions

Only 22.52% of the stock of Tempest Therapeutics is held by institutions.

TPST Stock Analysis - Frequently Asked Questions

How have TPST shares performed this year?

Tempest Therapeutics' stock was trading at $4.40 at the beginning of 2024. Since then, TPST stock has decreased by 79.6% and is now trading at $0.8984.
View the best growth stocks for 2024 here.

How were Tempest Therapeutics' earnings last quarter?

Tempest Therapeutics, Inc. (NASDAQ:TPST) released its earnings results on Tuesday, November, 12th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.37) by $0.04.

When did Tempest Therapeutics' stock split?

Tempest Therapeutics's stock reverse split before market open on Friday, June 25th 2021. The 1-15 reverse split was announced on Friday, June 25th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 28th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Who are Tempest Therapeutics' major shareholders?

Top institutional investors of Tempest Therapeutics include Geode Capital Management LLC (0.87%), Fullcircle Wealth LLC (0.28%), Empower Advisory Group LLC (0.14%) and XTX Topco Ltd (0.10%). Insiders that own company stock include Thomas Woiwode, Versant Venture Capital Vi, L, Stephen R Brady, Justin Trojanowski, Samuel Whiting and Thomas W Dubensky.
View institutional ownership trends.

How do I buy shares of Tempest Therapeutics?

Shares of TPST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Tempest Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Tempest Therapeutics investors own include Meta Platforms (META), Cloudflare (NET), NVIDIA (NVDA), Snowflake (SNOW), Tesla (TSLA), Intel (INTC) and Pfizer (PFE).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 11/21/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 3/18/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TPST
• CUSIP: N/A
• CIK: 1544227
• Web: www.millendo.com
• Phone: 415-798-8589
• Fax: N/A
• Employees: 20
• Year Founded: 2012

Price Target and Rating

• Average Stock Price Target: $20.00
• High Stock Price Target: $47.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +2,126.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.53)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-29,490,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -187.44%
• Return on Assets: -82.61%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.69
• Quick Ratio: 1.69

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.39 per share
• Price / Book: 0.65

Miscellaneous

• Outstanding Shares: 25,210,000
• Free Float: 24,023,000
• Market Cap: $22.65 million
• Optionable: Optionable
• Beta: -1.78